- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01105481
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients (M1106)
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients: A 14-week Randomized, Double-blind and Placebo-controlled Trial
This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and clinical assessment. Via chart-review, clinical data of diagnosis, disease course and previous treatment outcome, and concomitant psychotropic agents are obtained. Clinical phenomenology, including psychopathology, psychotic and mood symptoms severity and side effect of psychotropic medication are assessed by clinical interview and observation, which are conducted by experienced clinicians. Blood sample will be also obtained from the subjects for measuring the baseline clozapine drug level and extracting DNA for further analysis. Subjects fulfilling the criteria of treatment-resistant schizophrenia with poor response to adequate dose and duration of clozapine treatment are eligible for the clinical trial phase of 14-week randomized, placebo-controlled amisulpride add-on study. In this phase, subjects are randomly allocated to amisulpride augmentation treatment group and placebo treatment group. Subjects in the former group will receive clozapine and amisulpride combination treatment, while in the latter group will receive clozapine and placebo. Outcomes of clinical efficacy and safety are carefully evaluated by experienced and well-trained research stuffs in the 14 weeks of clinical study period.
All of the above studies will be conducted in four hospitals, including DOH Bali Psychiatric Hospital, DOH Tao-yan Psychiatric hospital, and the Ju-Shang Psychiatric Hospital. Subjects will be recruited from the chronic in-patient settings from these three hospitals.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Taipei County, Taiwan
- Bali Psychiatric Center
-
Tao-Yuan, Taiwan
- Departments of Psychiatry, Tao-yuan Psychiatric Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DSM-IV diagnosed schizophrenic patients;
- Age between 18 and 60;
- Before treatment with clozapine, documented treatment failure of two antipsychotics for an adequate duration of 6 weeks and in a sufficient dose of 600 mg/day of chlorpromazine equivalents;
- Documented failure to show a satisfactory clinical response to an adequate clozapine treatment, defined as at least clozapine 300 mg/day for 3 months or a plasma drug level of 350ng/ml;
- At least moderately ill, defined as with a Clinical Global Impression (CGI) greater than 4 or PANSS total score greater than 75;
- Persistent positive psychotic symptoms, with rating scores of moderate or worse on at least two of four positive symptom items (delusion, conceptual disorganization, hallucinatory behavior, and suspiciousness/persecution) on Positive and Negative Syndrome Scale (PANSS);
Exclusion Criteria:
- Patients with concomitant treatment with lithium, anti-convulsants, antidepressants and other antipsychotic medication ;
- Patients with underlying severe medical illness, such as cardiovascular disease, cerebrovascular disease, bone marrow suppression or epilepsy;
- Patients with comorbid diagnosis of substance dependence;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: amisulpride add-on
|
At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day.
Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability.
All of the add-on amisulpride will be provided to subjects at night.
To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
|
PLACEBO_COMPARATOR: placebo add-on
|
For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1.
On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively.
and adjunctive amisulpride, with a starting dose of 200 mg per day.
Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability.
To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Symptom Scale(PANSS) total score change
Time Frame: 12 wks after treatment
|
The change from baseline of the Positive and Negative Symptom Scale (PANSS) total score.
|
12 wks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Symptom Scale (PANSS) positive-symptom subscale score
Time Frame: 12 wks after treatment
|
The change from baseline of the Positive and Negative Symptom Scale (PANSS) positive-symptom subscale score (sum of item P1 to P7)
|
12 wks after treatment
|
Positive and Negative Symptom Scale (PANSS) negative-symptom subscale score
Time Frame: 12 wks after treatment
|
The change from baseline of the Positive and Negative Symptom Scale (PANSS) negative-symptom subscale score (sum of item N1 to N7)
|
12 wks after treatment
|
Positive and Negative Symptom Scale (PANSS) general psychopathology score
Time Frame: 12 wks after treatment
|
The change from baseline of the Positive and Negative Symptom Scale (PANSS) general psychopathology subscale score (sum of item G1 to G14)
|
12 wks after treatment
|
Clinical Global Impressions (CGI) scale score
Time Frame: 12 wks after treatment
|
The change from baseline of the Clinical Global Impressions (CGI) scale score
|
12 wks after treatment
|
Brief Psychotic Rating Scale (BPRS) total score
Time Frame: 12 wks after treatment
|
The change from baseline of the Brief Psychotic Rating Scale (BPRS) score
|
12 wks after treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Dopamine Agents
- Dopamine Antagonists
- Antidepressive Agents, Second-Generation
- Amisulpride
Other Study ID Numbers
- M1106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment-resistant Schizophrenia
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
University of California, Los AngelesPoloMar Health LLCNot yet recruiting
-
All India Institute of Medical Sciences, BhubaneswarNot yet recruitingDifference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia
Clinical Trials on Amisulpride add-on
-
University Hospital, BonnClemens Mielacher, University Hospital, BonnCompletedDepressive Disorder | Depression | Depressive Disorder, Major | Depressive EpisodeGermany
-
Mosaic Life CareMissouri Western State UniversityTerminatedBrain Injuries | Brain Concussion | Athletic Injuries | Diffuse Axonal Injury | Injury, Brain, TraumaticUnited States
-
Italian Society of DiabetologyAssociazione Nazionale Medici Cardiologi Ospedalieri; Associazione Medici Diabetologi...UnknownCardiovascular Disease | Type 2 Diabetes MellitusItaly
-
Central Institute of Mental Health, MannheimRecruiting
-
Taipei Veterans General Hospital, TaiwanRecruitingDigestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Esophageal Neoplasms | Esophageal DiseasesTaiwan
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Radboud University Medical Center; Bernhoven HospitalCompleted
-
Heidelberg UniversityHector-Stiftung; Schwabe-Wenex International Ltd; Cefak KG, Kempten; Ursapharm,...Completed
-
University of JaenUniversity Rovira i Virgili; Universidad Miguel Hernandez de ElcheRecruitingAnxiety Disorders and Symptoms Depressive Symptoms | Risk Factors (Rejection, Bullying/Cyberbullying, Addictions, Healthy Lifestyle Habits, Exam Stress Management, Ecoanxiety, Expressed Emotion)Spain
-
InxMed (Shanghai) Co., Ltd.RecruitingPlatinum-resistant Ovarian CancerChina
-
SOTIO a.s.CompletedStage IV Non-small Cell Lung CancerCzechia, Slovakia